Management holds a KOL conference call to discuss interim data from the Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD) on December 6 at 2 pm. Webcast Link
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LUMO:
- Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
- Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Piper ‘not concerned’ about two outliers in Lumos’ OraGrowtH210 rhGH cohort
- Lumos Pharma downgraded to Hold from Buy at Jefferies
- Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates